NCT00823524View on ClinicalTrials.gov

Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions
Brain and Central Nervous System TumorsChronic Myeloproliferative DisordersLeukemiaLymphomaLymphoproliferative DisorderMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative NeoplasmsUnspecified Adult Solid Tumor, Protocol Specific
Interventions
BIOLOGICAL

donor natural killer cell infusion

give patients donor-derived NK cells 2 to 3 weeks after HLA-haploidentical hematopoietic cell transplantation

Trial Locations (1)

138-736

University of Ulsan, Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
collaborator

Korea Research Institute of Bioscience & Biotechnology

OTHER_GOV

lead

Asan Medical Center

OTHER